Antiviral Discovery for Highly Pathogenic Emerging Viruses

Herausgeber: Muñoz-Fontela, César; Delgado, Rafael

• Gebundenes Buch

Produktbeschreibung

New antiviral drugs are urgently needed. Recent outbreaks caused by viruses with great epidemiological impact such as Zika, or extraordinary virulence such as Ebola, Nipah, Lassa, Crimean-Congo haemorrhagic fever highlight the current lack of clinically proven vaccines and treatments for these potentially catastrophic agents. Antiviral Discovery for Highly Pathogenic Emerging Viruses comprehensively outlines the state-of-the-art in antiviral drug discovery including identification of targets, screening strategies and the current pipeline of antiviral candidates including regulatory issues. The book also addresses the challenges faced in proceeding from pre-clinical studies to animal models and clinical trials with these highly pathogenic agents. Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book provides a complete overview of the latest progress in the field, recent advances and the challenges that remain in developing these highly pathogenic agents. Illustrated throughout with case studies this book is a valuable resource in this complex and multidisciplinary field.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: RSC Publishing
• Seitenzahl: 308
• Erscheinungstermin: 8. Dezember 2021
• Englisch
• Abmessung: 239mm x 160mm x 23mm
• Gewicht: 612g
• ISBN-13: 9781788015646
• ISBN-10: 1788015649
• Artikelnr.: 58293962

Inhaltsangabe

Antivirals for Emerging Viruses An Introduction; Overview of Antiviral Drug
Discovery and Development: Antiviral Therapy: Viral versus Host Targets;
Vaccine development in the midst of a crisis: the 2013-2016 West African
Ebola Virus Disease Outbreak; Antiviral Discovery for Coronavirus: SARS and
MERS CoV; Antiviral Discovery for Highly pathogenic paramyxovirus: Nipah
and Hendra virus; GS-5734 (Remdesivir): Development and activity on
different viral families; Antiviral Discovery for Emergent viruses in
animal and human health; Glycochemistry and Glycobiology in antiviral
treatment; Special issues in drug development for BSL4 agents: Animal
Models; Antiviral discovery for Influenza virus/Avian Influenza virus;
Antiviral therapies against Arenaviruses; Small-Moleclule Antiviral
Strategies for Ebola Virus and other filoviruses; Antiviral Strategies for
Ebola Virus and other filoviruses. Monoclonal Antibodies; Repurposing
approved drugs to block viral infection; Identification of novel receptors
on primary target cells as therapeutic strategies against Highly Pathogenic
Emerging Viruses